Activity
1 event
- Exit10 Aug 2026EUR 3.3M
Oculis acquires rights to Privosegtor from Accure Therapeutics for $3.8 million and shares.
Acquisition
▸Source: Viðskiptablaðið
“Heildarkaupverðið felur í sér 3,8 milljóna dala staðgreiðslu, auk útgáfu allt að 2,05 milljóna almennra hluta í Oculis.”
People
1 person
Riad Sherif
CEO
The newsletter
One issue a week. Tuesday at 06:00 CET.
Funding rounds, exits, hires, and launches from eight Nordic and Baltic countries. Read in under five minutes, with one editor’s judgement on every issue.
No ads · No algorithmic feed · Free